The Diabetic Nephropathy Market has exhibited significant growth, valued at USD 2.33 billion in 2023. Projections suggest further expansion, with expectations reaching USD 3.72 billion by 2031. This growth underscores the increasing prevalence of diabetic nephropathy, a severe complication of diabetes, and the growing need for effective treatment options to manage this condition. With an anticipated compound annual growth rate (CAGR) of 6.04% over the forecast period from 2024 to 2031, the market is poised for steady development, driven by factors such as rising diabetic populations, advancements in therapeutic interventions, and increased awareness about kidney health among diabetic patients.